CARISMA Therapeutics (FRA:W2J) LT-Debt-to-Total-Asset : 0.02 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CARISMA Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.02.

CARISMA Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.01) to Dec. 2024 (0.02). It may suggest that CARISMA Therapeutics is progressively becoming more dependent on debt to grow their business.

CARISMA Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for CARISMA Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics LT-Debt-to-Total-Asset Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.05

0.49

0.01

0.02

CARISMA Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial									0.01	0.05	0.02	0.02	0.02

CARISMA Therapeutics LT-Debt-to-Total-Asset Calculation

CARISMA Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.711	/	29.087
	=	0.02

CARISMA Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.711	/	29.087
	=	0.02

CARISMA Therapeutics (FRA:W2J) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CARISMA Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CARM:USA

Address

3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines